The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | Recent advances in the treatment of patients with myeloma: ADCs, antibodies and CAR-T
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the therapeutic landscape for patients with multiple myeloma, highlighting recent advances in the development of antibody-drug conjugates (ADCs) such as belantamab mafodotin, as well as novel monoclonal antibodies such as daratumumab and isatuximab which target CD38 and have shown efficacy in the relapsed/refractory (R/R) setting. Finally, Dr Cerchione outlines the potential of CAR-T cell therapies and bispecific antibodies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda Consulting or Advisory Role – Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi; SERVIER; Stemline Therapeutics; Takeda Speakers’ Bureau – Abbvie; Amgen; BeiGene; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Menarini; Pfizer; Sanofi/Aventis; SERVIER; Stemline Therapeutics; Takeda
